1. Antonijoan R. et al. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers. Curr Med Res Opin. 2017 Jan;33(1):129-136.
  2. Arnold SV et al. Circ Cardiovasc Qual Outcomes. 2016;9(5): 554–559.
  3. Bassetti M, et al. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering. Future Microbiol 2018;13:1081–1094.
  4. Bassetti M. et al. Infect Dis Ther. 2025;14(5):973-989
  5. Becker, M.A. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.
  6. Brade KD, et al. Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. Infect Dis Ther 2016;5(1):1–15.
  7. Bundesamt für Gesundheit: Spezialitätenliste, www.spezialitätenliste.ch.
  8. Chaitman BR et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA. 2004;291:309-16.
  9. Church M.K. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm Res. 2011 Dec;60(12):1107-12.
  10. Diedrichs H et al. Application of Ranolazine in stable angina pectoris therapy (ARETHA): Real-world data from an observational study. J Clin Exp Cardiolog 2015;6:12.
  11. Fachinformation Adenuric®, www.swissmedicinfo.ch.
  12. Fachinformation Bilaxin® Lingual, www.swissmedicinfo.ch.
  13. Fachinformation Bilaxten® Augentropfen, www.swissmedicinfo.ch.
  14. Fachinformation Bilaxten® KIDS, www.swissmedicinfo.ch.
  15. Fachinformation Bilaxten® Schmelztabletten, www.swissmedicinfo.ch.
  16. Fachinformation Bilaxten®, www.swissmedicinfo.ch.
  17. Fachinformation Brivex, www.swissmedicinfo.ch.
  18. Fachinformation INVOKANA®, www.swissmedicinfo.ch.
  19. Fachinformation Lioton 1000 Gel®, www.swissmedicinfo.ch.
  20. Fachinformation Nebilet® Plus , www.swissmedicinfo.ch.
  21. Fachinformation Nebilet® Tabletten, www.swissmedicinfo.ch.
  22. Fachinformation Quofenix, www.swissmedicinfo.ch.
  23. Fachinformation Ranexa®, www.swissmedicinfo.ch.
  24. Fachinformation Tenkasi® 1200 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, www.swissmedicinfo.ch.
  25. Fachinformation Tenkasi® 400 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, www.swissmedicinfo.ch.
  26. Fachinformation Vaborem, www.swissmedicinfo.ch.
  27. Fachinformation Vascord® HCT, www.swissmedicinfo.ch.
  28. Fachinformation Vascord®, www.swissmedicinfo.ch.
  29. Fachinformation VOKANAMET®, www.swissmedicinfo.ch.
  30. Fachinformation Votum® Plus, www.swissmedicinfo.ch.
  31. Fachinformation Votum®, www.swissmedicinfo.ch.
  32. Gomes P.J. et al. Bilastine 0.6% preservative-free eye drops, a once-daily treatment for allergic conjunctivitis. J Investig Allergol Clin Immunol. 2024; Vol. 34(3).
  33. Gomes P.J. et al. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study. J Investig Allergol Clin Immunol. 2023 Jul 27;33(4):271-280.
  34. Gouba N, Raoult D, Drancourt M. Med Mal Infect. 2015;45(1-2):9-16.
  35. Hecker SJ, et al. Discovery of a Cyclic Boronic Acid ß-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem 2015;58(9):3682–3692.
  36. Horak F. et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010 May;59(5):391-8.
  37. https://pubchem.ncbi.nlm.nih.gov/patent/LU-91682-I2 (Zugriff: 23.07.2025)
  38. Karim et al. Int J Food Microbiol. 2020; 16:333:108818.
  39. Kawauchi H. et al. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties. Int J Mol Sci. 2019 Jan 8;20(1).
  40. Li Y et al. Hypertension. 2010;55:1040-8.
  41. Lomovskaya O, et al. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017;61(11):e01443–17.
  42. Novelli A, et al. Expert Rev Anti Infect Ther. 2020 Jul;18(7):643-655.
  43. Pulido-Cejudo A. et al. Ther Adv Infectious Dis 2017;4(5):143–161.
  44. Quarella et al. Genome Announc. 2016; 4(5):e00923-16.
  45. Schumacher, H.R. Jr et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-194.
  46. Smith DH et al. Am J Cardiovasc Drugs. 2005;5:41–50.
  47. Stone PH. Cardiol Clin 2008; 26:603-14.
  48. Tagliamonte E, et al. Echocardiography 2015;32(3):516-21.
  49. Tice A. Clin Infect Dis. 2012;54(3):s239-s2943.
  50. Timmis AD. et al., Eur Heart J 2006; 27(1):42-8.
  51. Turval S.r.l. Trial 143: University of Perugia, Department of Biology and Agrodietary Biotechnologies. Internal technical reports.
  52. Turval S.r.l. Trials 125, 132, and 138. University of Perugia, Department of Biology and Agrodietary Biotechnologies. Internal technical reports.
  53. Turval S.r.l. Trials 84.01 and 84.02: University of Perugia, Department of Biology and Agrodietary Biotechnologies. Internal technical reports.
  54. Van Bambeke F. Future Microbiol 2015;10(7):1111–1123.
  55. Wassilew SW et al. Antiviral Res. 2003 ;59:49–56.
  56. Wassilew SW et al. Antiviral Res. 2003 ;59:57–60.
  57. Weir et al. J Clin Hypertens. 2011;13:404-12.
  58. Whelton, A. et al. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med. 2013;125(1):106-114.
  59. Willis LH, Slentz CA, Johnson JL, et al. Am J Cardiol. 2019;124(5):655–660.
  60. Wunderink RG, et al. Infect Dis Ther. 2018, Dec;7(4):439-455.
  61. Zaccardi F, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016;18(8):783–794.
  62. Zannad F et al. Fundamental & Clinical Pharmacology, 2007;21:181–90.